Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of
IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with
advanced solid tumors